AUTHOR=Faustmann Philipp , Schroeder Jan C. , Riedel Andreas , Schürch Christian M. , Killinger Simon , Phely Laurent , Mix Lucas , Lengerke Claudia , Häring Max-Felix 

TITLE=Real-world data of azacitidine for relapsed/refractory nodal T-follicular helper cell lymphoma in 11 patients

JOURNAL=Frontiers in Hematology

VOLUME=Volume 4 - 2025

YEAR=2025

URL=https://www.frontiersin.org/journals/hematology/articles/10.3389/frhem.2025.1638236

DOI=10.3389/frhem.2025.1638236

ISSN=2813-3935

ABSTRACT=Relapsed or refractory (r/r) nodal T-follicular helper cell lymphoma of the angioimmunoblastic type is a rare disease with a dismal prognosis. This disease usually harbors mutations in epigenetic modifiers. A standard of treatment for an r/r disease is not known. Here, we report real-world data of 11 patients with a median age of 73 years, treated with azacitidine, a hypomethylating agent. Overall survival was 182 days. Five patients died from progressive disease; three were in complete remission after allogeneic stem cell transplantation; two were in complete remission, still receiving azacytidine; and one was under treatment for relapse. The treatment was well-tolerated despite the advanced age, and there was a high burden of comorbidities with a median hematopoietic cell transplantation-specific comorbidity index (HCT-CI) of 5, a score for identifying relevant comorbidities. However, a grade 3 or 4 hematological toxicity occurred in nine patients. Azacitidine may be a suitable treatment option for some patients with r/r nodal T-follicular helper cell lymphoma.